The economic impact of once-daily versus conventional administration of gentamicin and tobramycin

PharmacoEconomics

Volumn 10, Issue 5, 1996, Pages 494-503

  Mithani, Hanif ^a   Brown, Glen ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

ADULT; AGED; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHARMACOECONOMICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0029822708     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610050-00007     Document Type: Article

References (25)

1. Nordstrom L, Lerner SA. Single daily dose therapy with aminoglycosides. J Hosp Infect 1991; 18 Suppl. A: 117-29
2. Tulkens PM. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Agents Chemother 1991; 27 Suppl. C: 49-61
3. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; .35: 399-405
4. Zhanel GG, Ariano RE. Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity? Ren Fail 1992; 14: 1-9
5. Hustinx WNM, Hoepelman IM. Aminoglycoside dosage regimens: is once daily enough? Clin Pharmacokinet 1993; 25: 427-32
6. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9
7. Craig WA. Vogelman B. The postantibiotic effect. Ann Intern Med 1987; 106: 900-2
8. Mandell LA, Bergeron MG, Ronald AR, et al. Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study. J Infect Dis 1989; 160: 433-41
9. Health Sciences Association of British Columbia, Health Labour Relations Association of British Columbia. Master agreement I April 1992-31 March 1994. Vancouver: Health Sciences Association of BC
10. Hospital Employees' Union, Health Labour Relations Association of British Columbia. Master agreement 1991 - 1994. Vancouver: Hospital Employees' Union
11. Workload measurement systems. In: Guidelines for management information systems in Canadian health care facilities: diagnostic and therapeutic services - Pharmacy. Ottawa: Management Information Systems Project Steering Committee, 1985
12. British Columbia's Nurses' Union, Health Labour Relations Association of British Columbia. Master collective agreement 1 April 1991 - 31 March 1994. Vancouver: British Columbia's Nurses' Union
13. Vanhaeverbeek M. Siska G. Douchamps J. et al. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly, Int J Clin Pharmacol Ther Toxicol 1993; 31: 153-6
14. Maller R, Ahrne H. Eilard T. et al. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. J Antimicrob Chemother 1991; 27 Suppl. C: 121-8
15. de Vries PJ, Verkooyen RP, Leguit P. et al. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990; 9: 161-8
16. TerBraak EW. deVries PJ. Bouter KP. et al. Once-daily dosing regimen for aminoglycosides plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1991; 89: 58-66
17. Sturm AW. Netilmicin in the treatment of Gram-negative bacteraemia: single daily versus multiple daily dosage. J Infect Dis 1989; 159: 931-7
18. Beaucaire G, Leroy O, Beuscart C. et al. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991: 27 Suppl. C: 91-103
19. Marik PE. Lipman J. Kobilski S. et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753-64
20. Prins JM. Buller HR. Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993: 341: 335-9
21. McCormack JP, Jewessen PJ. A critical revaluation of the 'therapeutic range' of aminoglycosides. Clin Infect Dis 1992; 14: 320-39
22. Konrad F. Wagner R. Neumeister B. et al. Studies on drug monitoring in thrice and once daily treatment with aminoglvcosides. Intensive Care Med 1993; 19: 215-20
23. Brown G, McCormack JP. Monitoring of aminoglycosides [letter]. Intensive Care Med 1993: 19: 243
24. Hitt CH, Klepser ME, Nightingale CH, et al. Pharmacoeconomic impact of a once-daily aminoglycoside program [abstract], 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco. 348
25. Amaya-Diaz A, Okpara A. Egunike I. et al. Evaluation of efficacy and nephrotoxicity associated with once daily dosing of aminoglycosides [abstract], American Society of Hospital Pharmacists Midyear Clinical Meeting. 1994 Dec 4-8: Miami Beach. 398